It’s nice to have more tools in the toolbox so that we’re not trying to fit a square peg in a round hole,” one expert says.

At 6 months, the win ratio favored the device over optimal medical therapy, in large part driven by improved quality of life.

Underdiagnosis and undertreatment likely drive the profound effects observed in certain populations, says Juan Granada.

The IRIS-MAIN registry results did show some differences in nonfatal outcomes like stroke, MI, and revascularization.

The postapproval study makes the case that Symplicity Spyral reduces BP across a wide swath of real-world populations.

REMEDY-PILOT showed the safety and feasibility of using the device, but with no effects on perfusion or angina symptoms.

SIRONA tested the sirolimus DCB against seven commercially available paclitaxel DCBs. The study randomized 482 patients (mean ...

The trial is “a turning point” in the management of moderate AS, says Philippe Généreux, adding that the disease is not benign.

The rates of TLF were considerably lower than the investigators expected, leading to questions about experience and selection ...

Immediate costs are higher for TAVI, but patients and the healthcare system benefit long-term from earlier intervention.

SIMPLAAFY was a multicenter, open-label trial that included 1,857 patients (mean age 76 years; 43% women) with AF who underwent LAAO with the Watchman FLX Pro device (Boston Scientific) without ...

SAN DIEGO, CA—Patients treated with the Agent drug-coated balloon (DCB; Boston Scientific) have encouraging outcomes at 1 ...